March 14, 2023
Keio University School of Medicine
A research group from the Division of Neurology, Keio University School of Medicine, led by Senior Lecturer Tsubasa Takizawa, Professor Jin Nakahara, and Keiko Ihara (a sixth-year student at the same School of Medicine), investigated which patients with migraine being treated at Keio University Hospital would benefit from CGRP-related monoclonal antibodies, a new class of drugs for migraine. The results revealed that CGRP-related monoclonal antibodies were more effective in patients who were 1) older, 2) had fewer prior preventive medication failures, and 3) had no history of immune system disorders.
The results of this research were published in the online edition of The Journal of Headache and Pain on March 9, 2023 (JST).
Please see below for the full press release.